Roche could top Pfizer, Lilly by 2014

While Pfizer, Eli Lilly, J&J, GlaxoSmithKline and Sanofi-Aventis face expiring patents and a sizeable drop in rank in the coming years, Roche might hold strong and is poised to carry about 6 percent of the global prescription drug market in 2014. Ranked fifth in 2007, the company is also less at risk of losing revenue to genetic competitors. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.